This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| B.1.617.2 | |
|---|---|
| Name | B.1.617.2 |
B.1.617.2 is a notable lineage of the severe acute respiratory syndrome coronavirus 2 first described during the global pandemic that began in 2019. The lineage was identified through genomic surveillance programs and became associated with shifts in case incidence, public health policy, and vaccine evaluation in multiple jurisdictions. Multiple public health agencies, academic institutions, and international organizations tracked its spread and evaluated its impacts on clinical care and non-pharmaceutical interventions.
B.1.617.2 was assigned within the phylogenetic nomenclature framework used by international consortia such as the Global Initiative on Sharing All Influenza Data, the World Health Organization, and national reference laboratories including the Centers for Disease Control and Prevention and the Public Health England sequencing networks. Early reports emerged from sequencing studies by teams at institutions like the Indian Council of Medical Research, National Institute of Virology (India), and university laboratories collaborating with the Wellcome Sanger Institute and the University of Oxford. Taxonomic placement relied on methods developed by groups affiliated with the Nextstrain project and the Pango Network to define distinct SARS-CoV-2 lineages used by public health agencies, clinical research centers, and surveillance consortia.
Genomic characterization integrated whole-genome sequencing pipelines used at the Broad Institute, Imperial College London, and the European Centre for Disease Prevention and Control. Analyses by virology teams at the National Institutes of Health, Institute Pasteur, and university virology departments identified characteristic spike protein substitutions and non-spike changes that informed structural biology studies performed in laboratories such as those at the Max Planck Institute and Cold Spring Harbor Laboratory. Structural modeling by researchers collaborating with facilities like the European Molecular Biology Laboratory and cryo-electron microscopy groups at the University of Cambridge helped map amino acid changes onto receptor-binding domains studied in context with work from the Harrisons Research Center and clinical virology units at major hospitals.
Epidemiological investigations were undertaken by public health authorities including Public Health England, the Centers for Disease Control and Prevention, the European Centre for Disease Prevention and Control, and national ministries of health. Analyses used datasets from surveillance platforms run by the World Health Organization, academic consortia at Imperial College London, the University of Edinburgh, and modelling groups at the London School of Hygiene & Tropical Medicine and the University of Toronto. Contact tracing efforts employed frameworks developed by municipal public health units and case-control studies alongside cohort studies at hospitals such as Guy's and St Thomas' NHS Foundation Trust and the Karolinska University Hospital.
Clinical data were collected in hospitals and health systems including NHS England, the New York-Presbyterian Hospital, and tertiary centers affiliated with the All India Institute of Medical Sciences. Clinical researchers from institutions such as the Johns Hopkins University, the University of California, San Francisco, and the Mayo Clinic contributed patient-level analyses comparing outcomes, hospitalization rates, and intensive care unit admissions. Severity assessments were contextualized against prior waves monitored by surveillance programs coordinated with the World Health Organization and regional public health institutes like the Robert Koch Institute.
Neutralization studies were published by teams at vaccine manufacturers and research institutes including Pfizer–BioNTech, Moderna, AstraZeneca, and university laboratories at the University of Oxford and the Pasteur Institute. Effectiveness evaluations leveraged vaccination registries maintained by national agencies such as the Centers for Disease Control and Prevention, Public Health England, and provincial programs in Ontario and Victoria (Australia) alongside real-world effectiveness cohorts from academic centers like the University of Melbourne and the Karolinska Institutet. Immunology groups at institutes like the Ragon Institute and the La Jolla Institute for Immunology studied antibody and T-cell responses in convalescent and vaccinated cohorts.
Responses incorporated interventions coordinated by the World Health Organization, national bodies such as the Ministry of Health and Family Welfare (India), and regional authorities including State Council of the People's Republic of China health commissions and European ministries supported by the European Centre for Disease Prevention and Control. Measures included enhanced genomic surveillance at sequencing hubs like the Wellcome Sanger Institute, travel advisories issued by the European Union and bilateral agreements among countries, and vaccination campaigns administered through providers such as the National Health Service and mass vaccination sites organized with support from international partners like Gavi, the Vaccine Alliance.
Initial reports coincided with surveillance activities in regions covered by institutions such as the Indian Council of Medical Research and academic collaborations with the Harvard T.H. Chan School of Public Health and Stanford University. The lineage's international dissemination was documented in outbreak reports from continents monitored by the Pan American Health Organization, the Africa Centres for Disease Control and Prevention, and regional public health agencies in Southeast Asia and Europe. Its emergence influenced policy decisions in governments, parliamentary briefings, and emergency response planning by organisations including the United Nations and led to follow-up research published by journals associated with the Lancet and the New England Journal of Medicine.
Category:SARS-CoV-2 lineages